<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lim JT</submitter><funding>Ministry of Education - Singapore</funding><funding>National Medical Research Council</funding><pagination>103</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12632001</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Increased risk of post-acute sequelae was found to occur in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 reinfections). However, it is unclear whether these increases in post-acute risk are found in milder Omicron reinfections, or persist in a highly boosted population.&lt;h4>Methods&lt;/h4>We utilised national COVID-19 databases and healthcare-claims records of Singapore to construct SARS-CoV-2 infected and uninfected cohorts over periods of Delta, Omicron BA.1/2, BA.4/5 and XBB predominance (1 July 2021-28 February 2023). The 300-day risk and excess burdens of pre-specified new-incident diagnoses across cardiovascular, neuropsychiatric, endocrine, auto-immune, renal, respiratory and gastrointestinal domains was compared across SARS-CoV-2 re-infected individuals (N = 57,222), SARS-CoV-2-infected individuals without documented re-infection (N = 1,239,119), and population-based un-infected controls (N = 3,409,170). Risk trajectories between groups were compared to examine whether differences in risk of post-acute sequelae persisted over follow-up time.&lt;h4>Results&lt;/h4>There was an estimated 21% (hazards ratios (HR) = 1.21; 95% Confidence interval (CI) [1.15-1.28]) increase in risk of any post-acute sequelae, and increased post-acute risk of cardiovascular (HR = 1.20; 95% CI [1.09-1.32]), gastrointestinal (HR 1.26; 95% CI [1.16-1.38]), neurological (HR 1.32; 95% CI [1.23-1.42]), endocrine (HR 1.26; 95% CI [1.18-1.35]), respiratory (HR 1.63; 95% CI [1.44-1.83]) and renal (HR 1.28; 95% CI [1.12-1.47]) sequelae associated with SARS-CoV-2 reinfections. Associated risks of post-acute sequelae were greater in reinfections compared to first infections. Excess burdens per 1000 of any post-acute sequelae were also higher in reinfected individuals, and reinfected individuals also had higher outcome probabilities of post-acute sequelae over follow-up time. Risks of post-acute sequelae persisted in fully vaccinated and boosted individuals.&lt;h4>Conclusions&lt;/h4>Reinfection with SARS-CoV-2 is associated with increased risk of post-acute sequelae. Reducing burden of post-acute complications due to SARS-CoV-2 necessitates strategies for preventing reinfection, such as updated vaccines with better effectiveness against infection.</pubmed_abstract><journal>BMC global and public health</journal><pubmed_title>Multi-systemic risk of post-acute sequelae associated with SARS-CoV-2 reinfection.</pubmed_title><pmcid>PMC12632001</pmcid><funding_grant_id>Clinical Scientist New Investigator Grant</funding_grant_id><funding_grant_id>Start-up grant</funding_grant_id><pubmed_authors>Lim JT</pubmed_authors><pubmed_authors>Wee LE</pubmed_authors><pubmed_authors>Tan JYJ</pubmed_authors><pubmed_authors>Ponce LJ</pubmed_authors><pubmed_authors>Ong B</pubmed_authors><pubmed_authors>Tan KB</pubmed_authors><pubmed_authors>Chiew CJ</pubmed_authors><pubmed_authors>Lye DCB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Multi-systemic risk of post-acute sequelae associated with SARS-CoV-2 reinfection.</name><description>&lt;h4>Background&lt;/h4>Increased risk of post-acute sequelae was found to occur in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 reinfections). However, it is unclear whether these increases in post-acute risk are found in milder Omicron reinfections, or persist in a highly boosted population.&lt;h4>Methods&lt;/h4>We utilised national COVID-19 databases and healthcare-claims records of Singapore to construct SARS-CoV-2 infected and uninfected cohorts over periods of Delta, Omicron BA.1/2, BA.4/5 and XBB predominance (1 July 2021-28 February 2023). The 300-day risk and excess burdens of pre-specified new-incident diagnoses across cardiovascular, neuropsychiatric, endocrine, auto-immune, renal, respiratory and gastrointestinal domains was compared across SARS-CoV-2 re-infected individuals (N = 57,222), SARS-CoV-2-infected individuals without documented re-infection (N = 1,239,119), and population-based un-infected controls (N = 3,409,170). Risk trajectories between groups were compared to examine whether differences in risk of post-acute sequelae persisted over follow-up time.&lt;h4>Results&lt;/h4>There was an estimated 21% (hazards ratios (HR) = 1.21; 95% Confidence interval (CI) [1.15-1.28]) increase in risk of any post-acute sequelae, and increased post-acute risk of cardiovascular (HR = 1.20; 95% CI [1.09-1.32]), gastrointestinal (HR 1.26; 95% CI [1.16-1.38]), neurological (HR 1.32; 95% CI [1.23-1.42]), endocrine (HR 1.26; 95% CI [1.18-1.35]), respiratory (HR 1.63; 95% CI [1.44-1.83]) and renal (HR 1.28; 95% CI [1.12-1.47]) sequelae associated with SARS-CoV-2 reinfections. Associated risks of post-acute sequelae were greater in reinfections compared to first infections. Excess burdens per 1000 of any post-acute sequelae were also higher in reinfected individuals, and reinfected individuals also had higher outcome probabilities of post-acute sequelae over follow-up time. Risks of post-acute sequelae persisted in fully vaccinated and boosted individuals.&lt;h4>Conclusions&lt;/h4>Reinfection with SARS-CoV-2 is associated with increased risk of post-acute sequelae. Reducing burden of post-acute complications due to SARS-CoV-2 necessitates strategies for preventing reinfection, such as updated vaccines with better effectiveness against infection.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T17:24:40.671Z</modification><creation>2026-05-19T03:11:43.171Z</creation></dates><accession>S-EPMC12632001</accession><cross_references><pubmed>41258276</pubmed><doi>10.1186/s44263-025-00222-1</doi></cross_references></HashMap>